Neutrolis Inc. Appoints Caren Deardorf As Chief Business And Strategy Officer To Drive Growth And Pipeline Advancement

Neutrolis Inc., a clinical-stage biotechnology company focused on targeting Neutrophil Extracellular Traps (NETs) to treat autoimmune and inflammatory diseases, announced the appointment of Caren Deardorf as its Chief Business and Strategy Officer. In this role, she will lead the company’s corporate and pipeline strategy, business development efforts, and early commercial planning as Neutrolis continues to advance its clinical programs.

Ms. Deardorf brings more than 30 years of leadership experience in the biotechnology industry, with a strong background in commercialization, product launches, and building and scaling organizations. Her experience spans multiple therapeutic areas and includes a consistent track record of translating scientific innovation into successful commercial outcomes.

Anthony Aiudi, PharmD, MBA, Chief Executive Officer of the company, described Ms. Deardorf as a highly capable leader with a strong mix of strategic thinking and executional expertise. He noted that her ability to turn innovation into meaningful value will play a key role as the company moves its pipeline forward, builds strategic partnerships, and prepares for late-stage development and future growth.

Ms. Deardorf expressed that her career has been focused on creating value for both shareholders and patients, and that she is excited to join Neutrolis at an important stage in its development. She shared her enthusiasm for working with the team to address significant unmet needs in autoimmune diseases and to help shape the company’s future direction.

Before joining Neutrolis, Ms. Deardorf served as Chief Commercial and Strategy Officer at several biotechnology companies, including Editas Medicine, Magenta Therapeutics, and Ohana Biosciences, where she led commercial strategy, portfolio planning, and corporate development initiatives. Earlier in her career, she held multiple senior leadership roles at Biogen, where she was responsible for global product development and commercialization, including the successful launch of SPINRAZA®. She has also contributed to several major global product launches such as TECFIDERA®, TYSABRI®, and AVONEX®, and has gained broad experience across neurology, immunology, hematology, oncology, and rare diseases.

In addition to her industry experience, Ms. Deardorf holds an MBA from the Olin Graduate School of Business at Babson College and a Bachelor of Science degree in Biology from Tufts University. She currently serves on the board of directors of Crinetics Pharmaceuticals and is also involved with the Pan-Mass Challenge, a non-profit organization that raises funds for the Dana-Farber Cancer Institute.

With this appointment, Neutrolis Inc. continues to strengthen its leadership team as it works to advance its pipeline and develop new treatment approaches for autoimmune and inflammatory diseases.